PULM Stock Overview
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pulmatrix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.96 |
| 52 Week High | US$3.14 |
| 52 Week Low | US$1.55 |
| Beta | 0.95 |
| 1 Month Change | 20.99% |
| 3 Month Change | 10.73% |
| 1 Year Change | -32.65% |
| 3 Year Change | -89.90% |
| 5 Year Change | -90.49% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100
Jul 12Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?
Feb 22
Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?
Oct 29Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts
Aug 16Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 14We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate
May 27We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate
Feb 11Shareholder Returns
| PULM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.7% | -2.2% | -3.7% |
| 1Y | -32.6% | 11.6% | 20.5% |
Return vs Industry: PULM underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: PULM underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| PULM volatility | |
|---|---|
| PULM Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PULM has not had significant price volatility in the past 3 months.
Volatility Over Time: PULM's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 22 | Ted Raad | www.pulmatrix.com |
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine.
Pulmatrix, Inc. Fundamentals Summary
| PULM fundamental statistics | |
|---|---|
| Market cap | US$7.16m |
| Earnings (TTM) | -US$14.12m |
| Revenue (TTM) | US$7.30m |
1.0x
P/S Ratio-0.5x
P/E RatioIs PULM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PULM income statement (TTM) | |
|---|---|
| Revenue | US$7.30m |
| Cost of Revenue | US$15.52m |
| Gross Profit | -US$8.22m |
| Other Expenses | US$5.90m |
| Earnings | -US$14.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.87 |
| Gross Margin | -112.63% |
| Net Profit Margin | -193.49% |
| Debt/Equity Ratio | 0% |
How did PULM perform over the long term?
See historical performance and comparison